| Literature DB >> 25656043 |
Stefano Sivolella1, Marleen De Biagi2,3, Giulia Brunello1, Mario Berengo1, Vittorio Pengo4.
Abstract
The development of new orally administered anticoagulants, such as dabigatran, rivaroxaban, and apixaban, in the past few years has focused on avoiding some of the drawbacks associated with warfarin. This work aims to illustrate the main features of the most commonly used new oral anticoagulants, reviewing the current literature on the management of patients taking these drugs and needing oral and implant surgery, and discussing the currently proposed related guidelines.Entities:
Keywords: Apixaban; Dabigatran; Oral anticoagulants; Oral surgery; Rivaroxaban
Mesh:
Substances:
Year: 2015 PMID: 25656043 DOI: 10.1007/s10266-015-0195-4
Source DB: PubMed Journal: Odontology ISSN: 1618-1247 Impact factor: 2.634